<a href="https://www.fiercebiotech.com/biotech/novartis-ceo-continuing-evaluate-vivo-car-ts-no-deals-works" hreflang="en">Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts, but no deals in the works</a>
Novartis is currently evaluating the in vivo CAR-T space, but CEO Vas Narasimhan stated there are no immediate acquisition plans despite the company's interest in this area. The company is focusing on its immune reset portfolio, particularly the rapcabtagene autoleucel therapy for blood cancers and autoimmune conditions, while also engaging in strategic acquisitions to bolster its pipeline against generic competition.
For a professional tracking healthtech and biotech investments, the key insight is that while Novartis is actively evaluating the in vivo CAR-T space, they currently have no plans for acquisitions. However, the company remains vigilant for compelling opportunities and continues to build its pipeline with strategic acquisitions under $2 billion, focusing on early- to mid-stage molecules in core therapeutic areas. This suggests a strategic opportunity to monitor Novartis's moves for potential partnerships or investments in promising early-stage biotech companies within these domains.